Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer
Clicks: 5
ID: 329821
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.2
/100
5 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #59 of 62 articles by views in jnci cancer spectrum
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Adjuvant endocrine therapy (AET) reduces breast cancer (BC) recurrence but may adversely affect cardiometabolic health. We evaluated the association between AET adherence duration and 10-year risk of hypertension, dyslipidemia, diabetes, and mortality among postmenopausal women with early-stage hormone receptor-positive BC. METHODS: We conducted a prospective cohort study of 8,365 postmenopausal women with stage I-III hormone receptor-positive BC within Kaiser Permanente Northern California who initiated AET between 2005 and 2013. Adherence (proportion of days covered >80%) was assessed annually using prescription dispensing data. We estimated 10-year cumulative incidence (CI) under six adherence duration strategies (0-5 years) using sequentially doubly robust estimation, adjusting for demographic, clinical, lifestyle, and tumor characteristics. Analyses were stratified by AET type (aromatase inhibitor [AI]; tamoxifen [TAM]). RESULTS: Overall, 42.7% were adherent for ≥5 years. Compared with nonadherence, 5-year adherence was associated with higher 10-year CI of hypertension (absolute CI difference = 8.81% [95% confidence interval (CI): 4.25-13.4]), dyslipidemia (5.16% [0.31-10.0]), and diabetes (2.58% [0.02-5.14]), but lower all-cause death (10.7% [7.74-13.7]) and BC-specific death (5.37% [3.36-7.38]). Five-year AI adherence was associated with increased hypertension (9.37% [4.54-14.2]), dyslipidemia (6.84% [1.76-11.9]), and diabetes (3.29% [0.58-6.00]), whereas TAM adherence was associated only with hypertension (9.37% [4.54-14.2]). AI adherence was associated with higher dyslipidemia risk than TAM (9.86% [5.09-14.6]). CONCLUSIONS: AI adherence was associated with increased cardiometabolic risk, whereas TAM was associated only with hypertension risk. Despite these risks, AET was associated with improved survival. Further research should evaluate whether cardiometabolic risk factors influence cardiovascular events among BC survivors.
| Reference Key |
openalex_W7214361044
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jorge R Ledesma, Joshua Nugent, Richard Cheng, Jennifer M Specht, Cecile A Laurent, Janise Roh, Sayan Dasgupta, Allison Meisner, Samir R. Thadani, Heather Greenlee, Raymond Liu, Marilyn L. Kwan |
| Journal | jnci cancer spectrum |
| Year | 2026 |
| DOI |
10.1093/jncics/pkag095
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.